In addition, pharmacologic inhibition of sphingosine 1-phosphate receptor 3 (S1PR3), a bioactive lipid molecule expressed in breast cancer, resulted in TME remodeling via the recruitment of pro-inflammatory macrophages and improved the efficacy of anti-EpCAM CAR T-cell therapy in a murine breast cancer model [61]. Here, EPCAM is linked to breast cancer.